Pulmonary Arterial Hypertension
📧 Sign up to get email alerts when something new happens for Pulmonary Arterial Hypertension.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2016-08-09Clinical Trial Update: Anastrozole in Patients With Pulmonary Arterial Hypertension [Phase 2]
A Phase 2 trial evaluating anastrozole in patients with pulmonary arterial hypertension has completed and posted results.
-
FDA label_change · 2016-07-18FDA Approved: VELETRI — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
The FDA approved a supplemental application for VELETRI (epoprostenol) from Actelion Pharmaceuticals US, Inc., leading to changes to its lab…
-
CLINICAL_TRIALS research · 2016-07-12Clinical Trial Update: Prevalence of Pulmonary Arterial Hypertension in Patients With Connective Tissue Diseases in Egyptian Patients
This clinical trial update describes a study that aims to determine the prevalence of pulmonary arterial hypertension among Egyptian patient…
-
FDA approval · 2016-06-15FDA Approved: OPSUMIT — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
The FDA approved a supplemental application for OPSUMIT (macitentan) submitted by Actelion Pharmaceuticals US, Inc., reflecting an approved …
-
CLINICAL_TRIALS research · 2016-06-08Clinical Trial Update: Retrospective Analysis of Pulmonary Arterial Hypertension (PAH) and Related Complications in Juvenile Idiopathic Arthritis (JIA) Participants Treated With Biologic and Non-biologic Disease-modifying Anti-rheumatic Drugs (DMARDs)
This retrospective analysis investigates pulmonary arterial hypertension and related complications in Juvenile Idiopathic Arthritis patients…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2016-06-08Clinical Trial Update: Pulmonary Hypertension in Interstitial Lung Disease
Clinical trial update indicating completion of a study on pulmonary hypertension in interstitial lung disease. The sponsor is Groupe d'Etude…
-
CLINICAL_TRIALS trial_result · 2016-05-16Clinical Trial Update: Remodulin® to Oral Treprostinil Transition [Phase 2]
Phase 2 trial results update evaluating transitioning patients with pulmonary arterial hypertension from Remodulin (treprostinil) to oral tr…
-
CLINICAL_TRIALS trial_result · 2016-05-06Clinical Trial Update: Iron Status and Hypoxic Pulmonary Vascular Responses [NA]
A clinical trial conducted by the University of Oxford on iron status and hypoxic pulmonary vascular responses has completed.
-
CLINICAL_TRIALS research · 2016-05-03Clinical Trial Update: Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
Multi-center, web-based observational study examining pulmonary hypertension in systemic sclerosis/scleroderma patients has completed. Trial…
-
CLINICAL_TRIALS trial_result · 2016-04-18Clinical Trial Update: Efficacy and Safety Study of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH) [Phase 2]
Phase 2 trial evaluating the efficacy and safety of udenafil in patients with pulmonary arterial hypertension has completed.
-
CLINICAL_TRIALS trial_result · 2016-04-18Clinical Trial Update: Clinical Trial to Evaluate the Long-term Safety of Udenafil in Patient With PAH [Phase 2, Phase 3]
A phase 2/3 clinical trial evaluating the long-term safety of udenafil in patients with pulmonary arterial hypertension has completed. The s…
-
FDA approval · 2016-03-22FDA Approved: OPSUMIT — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
The FDA approved a supplemental application for OPSUMIT (macitentan) from Actelion Pharmaceuticals US, Inc., authorizing changes to the prod…
-
FDA approval · 2016-03-21FDA Approved: LETAIRIS — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for LETAIRIS (ambrisentan) by Gilead Sciences, Inc., related to labeling or indication updates f…
-
CLINICAL_TRIALS trial_result · 2016-03-21Clinical Trial Update: Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder
This clinical trial update notes termination of NCT00722254, a University of Utah study investigating reversible secondary myelofibrosis or …
-
CLINICAL_TRIALS trial_result · 2016-03-17Clinical Trial Update: Early Detection of Pulmonary Arterial Hypertension Using Cardiac Magnetic Resonance Imaging
A Mayo Clinic clinical trial evaluating the use of cardiac magnetic resonance imaging for early detection of pulmonary arterial hypertension…
-
CLINICAL_TRIALS trial_result · 2016-03-01Clinical Trial Update: Selexipag (ACT-293987) in Pulmonary Arterial Hypertension [Phase 3]
A Phase 3 trial evaluating selexipag for pulmonary arterial hypertension has completed and results were posted in 2016.
-
CLINICAL_TRIALS research · 2016-02-26Clinical Trial Update: Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension)
This clinical trial update provides insights into the epidemiology and treatment patterns of pediatric pulmonary arterial hypertension, high…
-
FDA label_change · 2016-02-22FDA Approved: OPSUMIT — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
FDA approved a supplemental application for OPSUMIT (macitentan) with updated labeling.
-
CLINICAL_TRIALS trial_result · 2016-02-22Clinical Trial Update: The Qutenza Patch as Treatment for Disabling Treprostinil (Remodulin) Infusion Site Pain [Phase 2]
Phase 2 clinical trial evaluating the Qutenza capsaicin patch to reduce pain at treprostinil (Remodulin) infusion sites in pulmonary hyperte…
-
FDA approval · 2016-02-17FDA Approved: OPSUMIT — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
The FDA approved a supplemental application for OPSUMIT (macitentan) from Actelion Pharmaceuticals US, Inc. The action is part of the supple…
-
CLINICAL_TRIALS trial_result · 2016-02-17Clinical Trial Update: Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
The ClinicalTrials.gov update reports results comparing the incidence of respiratory tract adverse events in patients with pulmonary arteria…
-
CLINICAL_TRIALS trial_result · 2016-02-17Clinical Trial Update: Safety Study of PLX-PAD Cells to Treat Pulmonary Arterial Hypertension (PAH) [Phase 1]
A Phase 1 safety trial evaluating PLX-PAD cells for pulmonary arterial hypertension has been terminated.
-
FDA approval · 2016-01-28FDA Approved: ORENITRAM — Supplemental Application (United Therapeutics Corporation)
The FDA approved a supplemental application for ORENITRAM (treprostinil) from United Therapeutics.
-
FDA approval · 2016-01-22FDA Approved: REMODULIN — Supplemental Application (United Therapeutics Corporation)
The FDA approved a supplemental application for Remodulin (treprostinil) submitted by United Therapeutics Corporation. This action pertains …
-
FDA approval · 2016-01-15FDA Approved: SILDENAFIL — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for sildenafil (generic) filed by Chartwell RX, LLC.